Helix BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Helix BioPharma şirketinin toplam hissedar öz sermayesi CA$-90.0K ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$1.5M ve CA$1.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$1.08m
Eşitlik	-CA$90.00k
Toplam yükümlülükler	CA$1.58m
Toplam varlıklar	CA$1.49m

Son finansal sağlık güncellemeleri

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

Mar 07

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Nov 03

Recent updates

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

Mar 07

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Nov 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HBP negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: HBP şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HBP borçsuzdur.

Borcun Azaltılması: HBP 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HBP şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 5.4 oranında tarihsel oranda büyümeye devam ederse HBP un bir yıldan az nakit akışı süresi vardır.

Helix BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Recent updates

New minor risk - Share price stability

New major risk - Negative shareholders equity

Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding

Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding

Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer

Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024

New major risk - Negative shareholders equity

Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding

Helix BioPharma Corp. Announces Executive Changes

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Helix BioPharma Corp. Announces CEO Changes

Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer

Helix BioPharma Corp. Appoints Gabrielle M Siegers as Head of Research Development Based Out of its Lab in Edmonton

High number of new and inexperienced directors

Helix BioPharma Corp. Appoints Namrata Malhotra as Corporate Secretary

Helix BioPharma Corp. Appoints Hatem Kawar as Chief Financial Officer

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it has received CAD 2.002 million in funding

Helix Biopharma Corp. Announces Board Changes

Helix BioPharma Corp. announced that it expects to receive CAD 2.002 million in funding

Helix Biopharma Corp. Announces Resignation of Krzysztof Saczek from the Board of Directors

Helix BioPharma Corp. Appoints Adam Uszpolewicz to its Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it expects to receive CAD 10 million in funding from The Lind Partners, LLC

Helix Biopharma Corp. Appoints Dr. Frank Gary Renshaw to the Scientific Advisory Board

New 90-day high: CA$1.01

Helix BioPharma Corp. announced that it has received CAD 3 million in funding

New 90-day high: CA$0.42

CAIAC Fund Management AG completed the acquisition of 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP).

Helix BioPharma Corp. announced that it has received CAD 1.1 million in funding

New 90-day low: CA$0.29

Helix BioPharma Corp., Annual General Meeting, Jan 28, 2021

New 90-day low: CA$0.30

CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million.

New 90-day low: CA$0.41

New 90-day low - CA$0.47

Biotech Opportunity Fund managed by CAIAC Fund Management AG acquired 19.8% stake in Helix BioPharma Corp. (TSX:HBP) for CAD 13.2 million.

New 90-day low - CA$0.51

A third-party purchaser acquired 15.5% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp.

Helix BioPharma Corp. to Report Q3, 2020 Results on Jul 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin